Clinical Trials Logo

Clinical Trial Summary

This is a Phase I, open-label, first in human study of HS269 tablet, a small molecule highly-selective RET Inhibitor. The dose-escalation study will assess the safety, tolerability, and pharmacokinetics of HS269 and determine the dose and schedule to be used in Phase II. Seventeen to thirty-six patients with advanced solid tumor may be enrolled in this study.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05058352
Study type Interventional
Source Zhejiang Hisun Pharmaceutical Co. Ltd.
Contact Caicun Zhou
Phone 021-65115006
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date October 2021
Completion date April 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02836600 - A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04890613 - Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation Phase 1
Recruiting NCT04390737 - Evaluate the Safety and Clinical Activity of HH2853 Phase 1
Active, not recruiting NCT04108676 - Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects Phase 1
Recruiting NCT05076396 - PM14 Administered Intravenously to Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04825392 - A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05065710 - A Study of ZL-1211 in Patients With Advanced Solid Tumor Phase 1/Phase 2
Not yet recruiting NCT05001516 - Study of LaNova Medicines(LM)-302 in Patients With Advance Solid Tumors Phase 1/Phase 2
Recruiting NCT04592653 - A Study of ALKS 4230 (Nemvaleukin Alfa) on the Tumor Microenvironment Phase 2
Active, not recruiting NCT03704246 - Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors Phase 2
Recruiting NCT05002270 - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation Phase 1/Phase 2
Not yet recruiting NCT05036291 - A Study of NB004 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04478461 - Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Recruiting NCT04135261 - A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors Phase 1
Not yet recruiting NCT05008445 - Study of LM-102 in Patients With Advance Solid Tumors Phase 1/Phase 2
Completed NCT01387321 - A Study of BYL719 in Adult Patients With Advanced Solid Malignancies Phase 1
Recruiting NCT05021367 - A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor Phase 1
Not yet recruiting NCT05051241 - A Study of GFH018 in Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT05009966 - Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor Phase 1